CureVac NV Financials
CVAC Stock | USD 2.87 0.13 4.74% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 2.56 | 2.5666 |
|
|
Investors should never underestimate CureVac NV's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor CureVac NV's cash flow, debt, and profitability to make informed and accurate decisions about investing in CureVac NV.
Net Income |
|
CureVac | Select Account or Indicator |
Understanding current and past CureVac NV Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of CureVac NV's financial statements are interrelated, with each one affecting the others. For example, an increase in CureVac NV's assets may result in an increase in income on the income statement.
Please note, the presentation of CureVac NV's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CureVac NV's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CureVac NV's management manipulating its earnings.
CureVac NV Stock Summary
CureVac NV competes with Stagwell, NETGEAR, WiMi Hologram, Anterix, and Kandi Technologies. CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid . The company was founded in 2000 and is headquartered in Tbingen, Germany. Curevac NV operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 764 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | NL0015436031 |
CUSIP | N2451R105 |
Location | Germany |
Business Address | Friedrich-Miescher-Strasse 15, Tbingen, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.curevac.com |
Phone | 49 7071 9883 0 |
Currency | USD - US Dollar |
CureVac NV Key Financial Ratios
Return On Equity | -0.54 | ||||
Operating Margin | (4.94) % | ||||
Price To Sales | 9.78 X | ||||
Revenue | 53.76 M | ||||
Gross Profit | (91.55 M) |
CureVac NV Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 130.6M | 1.5B | 1.2B | 860.5M | 788.2M | 838.7M | |
Other Current Liab | 13.3M | 56.1M | 171.4M | 44.7M | 88.0M | 70.9M | |
Net Tangible Assets | (48.2M) | 697.9M | 676.2M | 501.5M | 576.7M | 407.8M | |
Net Debt | 48.5M | (1.3B) | (782.6M) | (453.7M) | (360.6M) | (378.7M) | |
Retained Earnings | (515.9M) | (645.1M) | (1.1B) | (1.3B) | (1.6B) | (1.5B) | |
Accounts Payable | 5.3M | 17.6M | 122.3M | 68.2M | 46.4M | 49.3M | |
Cash | 30.7M | 1.3B | 811.5M | 495.8M | 402.5M | 565.5M | |
Other Assets | 6.3M | 7.5M | 5.6M | 3.0M | 1.0 | 0.95 | |
Net Receivables | 17.7M | 1.8M | 53.7M | 9.0M | 39.5M | 23.6M | |
Inventory | 6.2M | 14.5M | 56.2M | 24.0M | 24.8M | 23.6M | |
Other Current Assets | 1.2M | 48.3M | 14.0M | 20.3M | 9.0M | 17.5M | |
Total Liab | 173.4M | 800.0M | 469.8M | 327.2M | 271.3M | 391.5M | |
Net Invested Capital | 22.2M | 711.3M | 688.5M | 533.3M | 516.9M | 459.1M | |
Total Current Assets | 57.2M | 1.4B | 940.0M | 584.0M | 478.4M | 645.8M | |
Net Working Capital | 29.1M | 1.1B | 582.3M | 427.8M | 292.0M | 461.7M | |
Short Term Debt | 2.0M | 3.2M | 3.5M | 5.0M | 5.0M | 3.5M | |
Intangible Assets | 5.7M | 14.1M | 13.2M | 19.3M | 15.9M | 13.7M |
CureVac NV Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Tax Provision | (252K) | (726K) | (782K) | (126K) | 67K | 70.4K | |
Net Interest Income | (627K) | (20M) | (235K) | 302K | 5.5M | 5.7M | |
Interest Income | 833K | 2.1M | 10.1M | 4.0M | 12.9M | 13.6M | |
Interest Expense | 1.5M | 22.1M | 10.3M | 3.7M | 2.5M | 2.4M | |
Total Revenue | 17.4M | 48.9M | 103.0M | 67.4M | 53.8M | 55.6M | |
Gross Profit | (10.6M) | 34.7M | (135.2M) | (116.6M) | (70.6M) | (74.1M) | |
Operating Income | (99.5M) | (124.0M) | (412.3M) | (249.5M) | (274.2M) | (287.9M) | |
Ebit | (99.5M) | (136.7M) | (422.4M) | (235.5M) | (257.5M) | (270.3M) | |
Research Development | 43.2M | 113.8M | 815.9M | 62.6M | 115.7M | 218.7M | |
Ebitda | (91.5M) | (123.1M) | (386.5M) | (209.4M) | (234.1M) | (245.8M) | |
Cost Of Revenue | 28.0M | 14.2M | 238.2M | 184.0M | 124.4M | 111.2M | |
Income Before Tax | (100.1M) | (129.8M) | (412.5M) | (249.2M) | (260.0M) | (273.0M) | |
Net Income | (99.9M) | (129.1M) | (411.7M) | (249.0M) | (260.2M) | (273.2M) | |
Income Tax Expense | (252K) | (726K) | (782K) | (126K) | 198K | 207.9K |
CureVac NV Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (3.2M) | (8.3M) | (227.5M) | (47.9M) | (47.0M) | (49.3M) | |
Investments | 28.2M | (1.2M) | (127.9M) | (93.5M) | (61.7M) | (64.8M) | |
Change In Cash | 9.3M | 1.3B | (511.1M) | (315.7M) | (93.3M) | (88.7M) | |
Free Cash Flow | (99.2M) | 475.1M | (861.0M) | (379.4M) | (323.1M) | (339.2M) | |
Depreciation | 7.2M | 10.7M | 15.7M | 23.7M | 23.4M | 15.5M | |
Other Non Cash Items | 9.9M | 51.6M | (480.7M) | 57.2M | 29.5M | 31.0M | |
Capital Expenditures | 12.2M | 47.4M | 127.9M | 93.2M | 55.2M | 64.3M | |
Net Income | (100.1M) | (129.8M) | (412.5M) | (249.2M) | (260.2M) | (273.2M) | |
End Period Cash Flow | 30.7M | 1.3B | 811.5M | 495.8M | 402.5M | 565.5M |
CureVac Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CureVac NV's current stock value. Our valuation model uses many indicators to compare CureVac NV value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CureVac NV competition to find correlations between indicators driving CureVac NV's intrinsic value. More Info.CureVac NV is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At present, CureVac NV's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CureVac NV's earnings, one of the primary drivers of an investment's value.CureVac NV Systematic Risk
CureVac NV's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. CureVac NV volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on CureVac NV correlated with the market. If Beta is less than 0 CureVac NV generally moves in the opposite direction as compared to the market. If CureVac NV Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one CureVac NV is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of CureVac NV is generally in the same direction as the market. If Beta > 1 CureVac NV moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in CureVac NV Stock are looking for potential investment opportunities by analyzing not only static indicators but also various CureVac NV's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of CureVac NV growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
CureVac NV November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of CureVac NV help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of CureVac NV. We use our internally-developed statistical techniques to arrive at the intrinsic value of CureVac NV based on widely used predictive technical indicators. In general, we focus on analyzing CureVac Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build CureVac NV's daily price indicators and compare them against related drivers.
Information Ratio | (0.09) | |||
Maximum Drawdown | 16.27 | |||
Value At Risk | (4.51) | |||
Potential Upside | 4.74 |
Complementary Tools for CureVac Stock analysis
When running CureVac NV's price analysis, check to measure CureVac NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CureVac NV is operating at the current time. Most of CureVac NV's value examination focuses on studying past and present price action to predict the probability of CureVac NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CureVac NV's price. Additionally, you may evaluate how the addition of CureVac NV to your portfolios can decrease your overall portfolio volatility.
Transaction History View history of all your transactions and understand their impact on performance | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |